Soligenix Inc Stock OTC Bulletin Board
Stocks
US8342232084
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
| 05-28 | Soligenix - increases maximum offering under sales agreement by $2.96 million | RE |
| Market Cap | 5.31M 4.66M 4.31M 3.97M 7.49M 512M 7.58M 51.5M 20.15M 251M 19.94M 19.51M 866M | P/E 2026 * |
-0.4x | P/E 2027 * | -0.53x |
|---|---|---|---|---|---|
| Enterprise Value | 5.31M 4.66M 4.31M 3.97M 7.49M 512M 7.58M 51.5M 20.15M 251M 19.94M 19.51M 866M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.26% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 2006-07-31 | |
Jonathan Guarino
DFI | Director of Finance/CFO | 53 | 2019-09-10 |
| Chief Tech/Sci/R&D Officer | - | 2026-06-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 59 | 2009-10-07 | |
Gregg Lapointe
BRD | Director/Board Member | 67 | 2009-02-28 |
Robert Rubin
BRD | Director/Board Member | 80 | 2009-09-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.88% | +0.08% | +54.51% | +58.77% | 53.79B | |
| +1.80% | +5.16% | +53.09% | +86.95% | 54.69B | |
| +1.50% | -1.35% | +5.68% | +415.28% | 23.2B | |
| +0.18% | +2.13% | -15.22% | -14.97% | 23.31B | |
| +1.46% | +4.02% | +35.97% | -4.03% | 20.03B | |
| +0.30% | -2.68% | +30.50% | -33.10% | 17.31B | |
| 0.00% | -6.00% | +163.95% | +284.69% | 14.99B | |
| +1.49% | +1.49% | +31.63% | +654.98% | 15.36B | |
| +1.06% | +0.63% | +26.80% | +185.02% | 13.96B | |
| Average | +0.96% | -1.84% | +42.99% | +181.51% | 26.29B | |
| Weighted average by Cap. | +1.09% | -1.78% | +43.02% | +141.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -12.4M -10.87M -10.07M -9.27M -17.48M -1.19B -17.69M -120M -47.03M -585M -46.55M -45.55M -2.02B | -13.3M -11.66M -10.8M -9.94M -18.75M -1.28B -18.97M -129M -50.45M -628M -49.93M -48.85M -2.17B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
